Literature DB >> 7180739

Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192.

Z X Huang, P M May, K M Quinlan, D R Williams, A M Creighton.   

Abstract

Formation constants for the calcium(II), copper(II), iron(II), magnesium(II), manganese(II) and zinc(II) complexes of dl-NN'-dicarboxamidomethyl-NN'-dicarboxymethyl-1,2-diaminopropane (ICRF 198) and the 1,2-diamino-butane homologue (ICRF 226) have been measured potentiometrically at 37 degrees C and I=150 mmol dm-3 [NaCl]. The constants are used in computer simulation models to assess the relative avidity of these compounds for biologically essential metal ions in vivo. It is shown that the agents interact similarly with all of the ions studied except those of zinc(II), which are particularly strongly chelated by the hydrolysis product of ICRF 192. This effect could be responsible for the difference in cytotoxicity exhibited by the antitumour agent ICRF 159 (Razoxane) and its inactive homologue ICRF 192. However, the mechanism through which this might occur remains unclear.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180739     DOI: 10.1007/bf01965940

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  23 in total

1.  [Effect of the bis-dioxopiperazines ICRF 159 and ICRF 154 on the urinary excretion of cadmium in cadmium-poisoned rats (author's transl)].

Authors:  U Witting; H P Bertram; E Schumacher; G Ritter
Journal:  Int Arch Occup Environ Health       Date:  1979-01-15       Impact factor: 3.015

2.  Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells.

Authors:  K M Dawson
Journal:  Biochem Pharmacol       Date:  1975-12-15       Impact factor: 5.858

3.  Computer simulation of chelation therapy. Plasma mobilizing index as a replacement for effective stability constant.

Authors:  P M May; D R Williams
Journal:  FEBS Lett       Date:  1977       Impact factor: 4.124

Review 4.  Role of superoxide dismutase in cancer: a review.

Authors:  L W Oberley; G R Buettner
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

5.  Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic.

Authors:  A J Salsbury; K Burrage; K Hellmann
Journal:  Br Med J       Date:  1970-11-07

6.  Antitumour activity in a series of bisdiketopiperazines.

Authors:  A M Creighton; K Hellmann; S Whitecross
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

7.  Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

Authors:  E H Herman; R M Mhatre; D P Chadwick
Journal:  Toxicol Appl Pharmacol       Date:  1974-03       Impact factor: 4.219

8.  Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

Authors:  R J Woodman; R L Cysyk; I Kline; M Gang; J M Venditti
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

9.  Lead elimination of ICRF 158 in rats after chronic lead exposure.

Authors:  U Witting; E Hultsch
Journal:  Int Arch Occup Environ Health       Date:  1981       Impact factor: 3.015

10.  Multiple effects of calcium antagonists on plateau currents in cardiac Purkinje fibers.

Authors:  R S Kass; R W Tsien
Journal:  J Gen Physiol       Date:  1975-08       Impact factor: 4.086

View more
  12 in total

1.  The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.

Authors:  T K Yeung; R S Jaenke; D Wilding; A M Creighton; J W Hopewell
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.

Authors:  J L Buss; B B Hasinoff
Journal:  Agents Actions       Date:  1993-09

3.  The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1990-03

4.  Metal binding by pharmaceuticals. Part 3. Copper (II) and zinc (II) interactions with isoniazid.

Authors:  A Cole; P M May; D R Williams
Journal:  Agents Actions       Date:  1983-02

5.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.

Authors:  J R Baldwin; B A Phillips; S K Overmyer; N Z Hatfield; P K Narang
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Metal ion-tetracycline interactions in biological fluids. Part 5. Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance.

Authors:  M Brion; L Lambs; G Berthon
Journal:  Agents Actions       Date:  1985-12

7.  The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.

Authors:  B B Hasinoff; S V Kala
Journal:  Agents Actions       Date:  1993-05

8.  Metal binding by pharmaceuticals. Part 5. Interaction of Cd(II), Ni(II) and Pb(II) with the intracellular hydrolysis products of the anti-tumour agent ICRF 159 and its inactive homologue ICRF 192.

Authors:  P M May; M J Willes; D R Williams; A M Creighton
Journal:  Agents Actions       Date:  1984-10

Review 9.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

10.  Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.

Authors:  S L Maloney; D C Sullivan; S Suchting; J M J Herbert; E M Rabai; Z Nagy; J Barker; S Sundar; R Bicknell
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.